ACET Stock Forecast 2025-2026
Distance to ACET Price Targets
ACET Price Momentum
10 Quality Stocks Worth Considering Now
Researching Adicet (ACET) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ACET and similar high-potential opportunities.
Latest ACET Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ACET has a bullish consensus with a median price target of $7.00 (ranging from $4.00 to $8.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $0.78, the median forecast implies a 794.0% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from John Newman at Canaccord Genuity, projecting a 921.7% upside. Conversely, the most conservative target is provided by Soumit Roy at Jones Trading, suggesting a 410.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACET Analyst Ratings
ACET Price Target Range
Latest ACET Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACET.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | Citizens Capital Markets | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Feb 27, 2025 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Feb 6, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Feb 5, 2025 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Oct 16, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Sep 20, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $5.00 |
| Sep 19, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $0.00 |
| Sep 11, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $8.00 |
| Sep 11, 2024 | Jones Trading | Soumit Roy | Buy | Maintains | $4.00 |
| Sep 11, 2024 | HC Wainwright & Co. | Edward White | Neutral | Downgrade | $0.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
| Aug 14, 2024 | Canaccord Genuity | John Newman | Buy | Maintains | $19.00 |
| Jul 8, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
| Jun 24, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
| May 15, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $10.00 |
Adicet Bio, Inc. (ACET) Competitors
The following stocks are similar to Adicet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adicet Bio, Inc. (ACET) Financial Data
Adicet Bio, Inc. has a market capitalization of $64.71M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -65.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Adicet Bio, Inc. (ACET) Business Model
About Adicet Bio, Inc.
Develops innovative cancer therapies using T cells.
Adicet Bio focuses on creating allogeneic gamma delta T cell therapies for oncology, generating revenue through the development and commercialization of these advanced cancer treatments. Their proprietary technology platform enhances the effectiveness of these T cells, allowing for targeted therapies against various cancers.
The company operates in the growing immuno-oncology market, contributing to significant advancements in cancer treatment technologies and improving patient outcomes. Adicet Bio leverages scientific expertise and strategic partnerships to enhance its research and development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
152
CEO
Mr. Chen Schor BA, CPA, M.B.A.
Country
United States
IPO Year
2017
Website
www.adicetbio.comAdicet Bio, Inc. (ACET) Latest News & Analysis
Adicet Bio, Inc. reported Q4 and full-year 2024 results, planning to advance its gamma delta 1 CAR T cell therapies in 2025, with key milestones and preliminary data expected.
Adicet Bio's financial results and plans to advance CAR T cell therapies signal potential growth and innovation in biotech, impacting investor confidence and stock performance.
Adicet Bio, Inc. (Nasdaq: ACET) announced two abstracts accepted for presentation at the SITC 2025 Spring Scientific Meeting, March 12-14, 2025, in San Diego, focusing on gamma delta T cell therapies.
Adicet Bio's acceptance of abstracts for a prominent scientific meeting highlights its ongoing research progress and potential advancements in cancer therapies, which can boost investor confidence and stock value.
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
17 days agoAdicet Bio's ADI-001 has received Fast Track Designation from the FDA for treating systemic sclerosis in adults, potentially accelerating its development and review process.
FDA Fast Track Designation for Adicet Bio's ADI-001 enhances the drug's development prospects, potentially leading to quicker market entry, increased investor interest, and higher stock valuation.
Adicet Bio, Inc. (Nasdaq: ACET) received FDA Fast Track Designation for ADI-001, aimed at treating adult patients with refractory systemic lupus erythematosus.
FDA's Fast Track Designation for Adicet Bio's ADI-001 could accelerate its development, potentially leading to quicker market entry and increased revenue prospects for the company.
Adicet Bio, Inc. granted inducement awards for 28,600 non-qualified stock options at an exercise price of $0.89 per share to two new hires on January 31, 2025.
Adicet Bio's stock options grant to new hires signals confidence in growth and potential innovation, impacting investor sentiment and company valuation positively.
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
1 month agoAdicet Bio, Inc. (Nasdaq: ACET) CEO Chen Schor will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5-6, 2025, in New York.
Adicet Bio's CEO participation at a prominent biotech conference may boost visibility and investor confidence, potentially impacting stock performance and future funding opportunities.
Frequently Asked Questions About ACET Stock
What is Adicet Bio, Inc.'s (ACET) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Adicet Bio, Inc. (ACET) has a median price target of $7.00. The highest price target is $8.00 and the lowest is $4.00.
Is ACET stock a good investment in 2025?
According to current analyst ratings, ACET has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACET stock?
Wall Street analysts predict ACET stock could reach $7.00 in the next 12 months. This represents a 794.0% increase from the current price of $0.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adicet Bio, Inc.'s business model?
Adicet Bio focuses on creating allogeneic gamma delta T cell therapies for oncology, generating revenue through the development and commercialization of these advanced cancer treatments. Their proprietary technology platform enhances the effectiveness of these T cells, allowing for targeted therapies against various cancers.
What is the highest forecasted price for ACET Adicet Bio, Inc.?
The highest price target for ACET is $8.00 from John Newman at Canaccord Genuity, which represents a 921.7% increase from the current price of $0.78.
What is the lowest forecasted price for ACET Adicet Bio, Inc.?
The lowest price target for ACET is $4.00 from Soumit Roy at Jones Trading, which represents a 410.9% increase from the current price of $0.78.
What is the overall ACET consensus from analysts for Adicet Bio, Inc.?
The overall analyst consensus for ACET is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are ACET stock price projections?
Stock price projections, including those for Adicet Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
